Immuneering Corp IMRX
- atebimetinib — Pancreatic Ductal Adenocarcinoma Phase 3
- atebimetinib — Non-Small Cell Lung Cancer
- atebimetinib — Melanoma Phase 1
- envometinib Phase 1
- atebimetinib — Advanced Solid Tumors Phase 1
MEK (3 companies · 8 programs)
Companies with an active program directed at MEK.
Pasithea Therapeutics Corp. KTTA
- PAS-004 — Neurofibromatosis Type 1 Phase 1
- PAS-004 — Amyotrophic Lateral Sclerosis Preclinical
EXELIXIS, INC. EXEL
- COTELLIC — Melanoma Approved